Tinnitus in a patient with beta-thalassaemia intermedia on long-term treatment with desferrioxamine
- 1 September 1981
- journal article
- research article
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 57 (671) , 582-584
- https://doi.org/10.1136/pgmj.57.671.582
Abstract
Summary: A women with β-thalassemia intermedia, and iron overload following many years’ treatment with oral iron, was treated with subcutaneous desferrioxamine. During the course of this treatment she developed tinnitus, which was considered to be a rare complication of the use of this chelating agent. The mechanism of this effect is not understood.This publication has 9 references indexed in Scilit:
- CLINICAL TRIAL OF DESFERRIOXAMINE ENTRAPPED IN RED CELL GHOSTSThe Lancet, 1980
- Drug Toxicity of the Inner EarMedical Clinics of North America, 1979
- Advances in the use of iron-chelating agents for the treatment of iron overload.1979
- Computed tomography, ultrasound, and cholestatic jaundice.Gut, 1978
- IRON ABSORPTION IN IRON-LOADING ANÆMIAS: EFFECT OF SUBCUTANEOUS DESFERRIOXAMINE INFUSIONSThe Lancet, 1977
- Continuous Subcutaneous Administration of Deferoxamine in Patients with Iron OverloadNew England Journal of Medicine, 1977
- EFFECT OF DOSE, TIME, AND ASCORBATE ON IRON EXCRETION AFTER SUBCUTANEOUS DESFERRIOXAMINEThe Lancet, 1977
- SUBCUTANEOUS INFUSION AND INTRAMUSCULAR INJECTION OF DESFERRIOXAMINE IN PATIENTS WITH TRANSFUSIONAL IRON OVERLOADThe Lancet, 1976
- LONG‐TERM DESFERRIOXAMINE THERAPY IN THALASSEMIAAnnals of the New York Academy of Sciences, 1974